Table 1.
Selected studies evaluating extracorporeal photopheresis in acute graft-versus-host disease.
| Author (Reference) | Sample Size | Study Type | Underlying Hematologic Conditions | ORR | CR | aGVHD Organ Specific Responses | ||
|---|---|---|---|---|---|---|---|---|
| Skin | Liver | GI | ||||||
| Prospective studies | ||||||||
| Greinix et al. [9] | 59 | phase II prospective trial | AML, ALL, CML, other | 82% | 61% | 61% | ||
| Alousi et al. [10] | 51 | phase II, randomized, adaptive Bayesian design-based study (ECP + methylprednisolone vs. methylprednisolone) | AML/MDS and others | 72% | Visceral organ aGVHD: 47% | Visceral organ aGVHD: 47% | ||
| Retrospective studies | ||||||||
| Garban et al. [11] | 12 | retrospective | AL, CML, MDS, MM, Fanconi’s anemia, solid tumor | 75% | ||||
| Perfetti et al. [12] | 23 | retrospective | CML, AML, MM, MDS, MF, AA, Behcet syndrome | 52% | CR 66% | CR 27% | CR 40% | |
| Jagasia et al. [13] | 57 | retrospective comparative analysis (ECP vs. anti-cytokine therapy) | Not reported | 66% | 54% | ≤stage 2: 70% stage 3–4: 57% |
≤stage 2: 72% stage 3–4: 50% |
≤stage 2: 77% stage 3–4: 54% |
| Systematic reviews | ||||||||
| Abu-Dalle et al. [14] | 323 (9 studies)-54 patients analyzed for ORR | Systematic review | AL, AA, MDS, Thalassemia major, MM, CML, CLL, NHL, Fanconi’s anemia, solid tumor | 69% | 84% | 65% | ||
ORR: overall response rate; CR: complete response; PR: partial response; aGVHD: acute graft-versus-host disease; GI: gastrointestinal; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CLL: chronic lymphocytic leukemia; CML: chronic myelogenous leukemia; NHL: Non-Hodgkin’s lymphoma; MM: multiple myeloma; AA: aplastic anemia; ECP: extracorporeal photopheresis; AL: acute leukemia; MDS: myelodysplastic syndrome; MF: myelofibrosis.